TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8866582
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray fixed dosage of 1 mg x h‐1 during the day (n=44)
Study: 1503915
Drug: Mitozantrone, 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone, 14 mg m‐2 intravenously every 3 weeks (n = 30)
Study: 1503915
Drug: Megesterol acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megesterol acetate, 160 mg bd (n = 30)
Study: 6510459
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with terbutaline (Theophylline)
Study: 6510459
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with terbutaline (Enprofylline)
Study: 31422671
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (EPA+DHA) at a dose of 4 g/d
Study: 31422671
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (EPA only) at a dose of 4 g/d
Study: 31422671
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (4 g/d)
Study: 31422671
Drug: EPA-only (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-only (4 g/d) in REDUCE-IT trial
Study: 27075874
Drug: Interceptor LN
Normalized name: INTERCEPTOR
DrugBank: Milbemycin oxime (DB11531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interceptor LN (200 mg/m(2) alpha‐cypermethrin)
Study: 27075874
Drug: Conventional treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional treated nets (CTN) (40 mg/m(2) alpha‐cypermethrin)
Study: 17519148
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (OC) providing levonorgestrel (LNG) and ethinyl estradiol (EE) (150/30 microg per tablet)
Study: 9034228
Drug: NOCTE (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOCTE (1 x 30 mg at 21.00 h)
Study: 9034228
Drug: BID (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID (15 mg at 21.00 h and 15 mg at 09.00 h)
Study: 8379508
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg beta-carotene, 900 mg vitamin C, and 200 mg alpha-tocopherol for 6 months
Study: 8379508
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no vitamin supplements)
Study: 3092836
Drug: CS-514 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-514 (20 mg twice a day for 7 days)
Study: 3092836
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day for 7 days)
Study: 30151705
Drug: Mechanical debridement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement, 0.12% chlorhexidine mouthwash, and Lactobacillus reuteri (probiotic agent)
Study: 28848182
Drug: G‐CSF given
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF given during all 6 chemotherapy cycles
Study: 28848182
Drug: G‐CSF limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF limited to the first 2 chemotherapy cycles
Study: 22654449
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate (15 mg) with 2 L PEG solution
Study: 22654449
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 2 L PEG solution
Study: 22654449
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate (15 mg) with 2 L PEG solution (after excluding severe constipation)
Study: 22654449
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 2 L PEG solution (after excluding severe constipation)
Study: 22654449
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate (15 mg) with 2 L PEG solution (among previous colonoscopy experience subgroup)
Study: 11311761
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir from 36 weeks of gestation to term (group 1)
Study: 7543272
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of strontium (89)
Study: 7543272
Drug: Single large
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single large treatments
Study: 7543272
Drug: Extended courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended courses of treatment
Study: 21693215
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 7 postoperatively
Study: 8974126
Drug: Glutamine-supplemented total
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented total parenteral nutrition (TPN)
Study: 1451930
Drug: sultamicillin 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: sultamicillin 750 mg/day (n = 9)
Study: 1451930
Drug: sultamicillin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: sultamicillin 1500 mg/day (n = 46)
Study: 1451930
Drug: cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefuroxime axetil 500 mg/day (n = 51)
Study: 1451930
Drug: cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefuroxime axetil 1000 mg/day (n = 4)
Study: 6089581
Drug: Beta‐adrenoceptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐adrenoceptor blocker propranolol (160 mg/day)
Study: 29906310
Drug: Every-8-hour vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-8-hour vancomycin dosing
Study: 29906310
Drug: Every-8-hour cefepime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every-8-hour cefepime dosing
Study: 29906310
Drug: Every-12-hour vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-12-hour vancomycin dosing
Study: 29906310
Drug: Every-12-hour cefepime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every-12-hour cefepime dosing
Study: 18428198
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel plus high-dose calcitriol
Study: 16147846
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G suspension (Bicillin L‐A), 2.4 million units
Study: 1308263
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in young females
Study: 1308263
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in older females
Study: 1308263
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in both age groups
Study: 6730871
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia + epidural analgesia (local anaesthetics + morphine) continued for 72 h
Study: 15730434
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg) and herbal ephedra (20 mg ephedrine)
Study: 10908688
Drug: Homeopathic gel
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic gel
Study: 1462402
Drug: Diltiazem (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (n = 12, 240-360 mg)
Study: 1462402
Drug: Verapamil (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (n = 12, 240-360 mg)
Study: 3931216
Drug: misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 200 micrograms daily
Study: 3931216
Drug: misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: misoprostol 800 micrograms daily
Study: 3931216
Drug: cimetidine 1200
Normalized name: cimetidine 1200 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 1200 mg daily
Study: 18325056
Drug: Darifenacin controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin controlled-release 7.5 mg
Study: 18325056
Drug: Darifenacin controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin controlled-release 15 mg
Study: 12466781
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg) administered to patients showing signs of fatigue before reaching minimal HR (group A)
Study: 10728909
Drug: Intravenous etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous etoposide 150 mg/M2
Study: 10728909
Drug: Intravenous etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous etoposide 150 mg/M2 with mannitol 15 gm/M2
Study: 7493659
Drug: Dairy foods
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy foods group (n = 81) consuming approximately 30 grams of dairy protein daily
Study: 6787694
Drug: Intravenous pirenzepine
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pirenzepine 10 mg
Study: 28931011
Drug: Central information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central information highlighting flaws in the expert’s message (e.g., quality of the research presented by the expert)
Study: 28931011
Drug: Peripheral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral information about the expert (e.g., credentials)
Study: 12919340
Drug: Antiepileptic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic treatments
Study: 10675381
Drug: ATP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP treatment (10 intravenous 30-hour infusions at 2- to 4-week intervals)
Study: 10086544
Drug: Aprotinin therapy
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin therapy
Study: 8121306
Drug: Lipid-heparin infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-heparin infusion (Control)
Study: 8121306
Drug: Lipid-heparin infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-heparin infusion (Control) + Arginine (ARG)
Study: 26125769
Drug: emergency PCI
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: emergency PCI + rhBNP early treatment (Group B)
Study: 26125769
Drug: emergency PCI
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: emergency PCI + late rhBNP treatment (Group C)
Study: 24299712
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus CGMCC1.3724 (LPR) supplementation (1.6 × 10(8) colony-forming units of LPR/capsule, 2 capsules per day)
Study: 22990514
Drug: Intensive outpatient
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive outpatient therapy including mechanical lymph drainage using the RAGodoy® apparatus for 6 to 8 hours daily, Godoy & Godoy cervical stimulation technique for 20 minutes per day, and manual lymph drainage for one hour.
Study: 11334123
Drug: Montelukast (Cys-LT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (Cys-LT1 antagonist)
Study: 2421622
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) therapy for 1 week
Study: 2421622
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) therapy
Study: 29411446
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) during hospitalisation
Study: 29411446
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) post-discharge
Study: 29411446
Drug: NRT use
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT use during hospitalisation for those using six or more medications
Study: 24723432
Drug: venlafaxine Extended‐Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine Extended‐Release (XR) treatment
Study: 22178393
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg orally administered hydrocortisone
Study: 17363530
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (0.125 or 0.250 mg/kg), bortezomib (0.7, 1.0, or 1.3 mg/m(2)), ascorbic acid (1 g) i.v. on days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles.
Study: 17363530
Drug: Bortezomib (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (0.7 mg/m(2))
Study: 17363530
Drug: Bortezomib (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.0 or 1.3 mg/m(2))
Study: 15784480
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v (ProViva) in addition to conventional therapy (treatment group, n = 52)
Study: 15784480
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (control group, n = 51)
Study: 7615313
Drug: MkII implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: MkII implant
Study: 7615313
Drug: Standard Brånemark
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Brånemark System implant
Study: 2262234
Drug: MPA-L (methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA-L (methyl prednisolone acetate with lidocaine)
Study: 23180154
Drug: α‐Lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐Lipoic acid (1,200 mg d(‐1) for 10 days)
Study: 18793232
Drug: Muscular counterpulsation
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscular counterpulsation (MCP) treatment for 30 minutes daily for the first eight postoperative days in addition to standard therapy.
Study: 18793232
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative treatment without counterpulsation (control group).
Study: 17382730
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus boosters
Study: 11573587
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml(-1) with glucose 8 mg ml(-1)
Study: 11573587
Drug: Bupivacaine 5
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 5 mg ml(-1) with glucose 80 mg ml(-1)
Study: 1215448
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg/70 kg)
Study: 7821012
Drug: Afterwork emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afterwork emollient cream
Study: 7821012
Drug: No cream
Normalized name: Oil, Multi Ingredient Topical application Oil [AVEENO CREAMY MOISTURIZING OIL]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No cream (controls)
Study: 31563660
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (20 g/day for 1 week, then 5 g/day for 7 weeks)
Study: 31537373
Drug: Multivitamin multimineral
Normalized name: Multivitamin multimineral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin multimineral supplement
Study: 28130378
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with the NOAC apixaban
Study: 28130378
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) therapy
Study: 24448329
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 220 mg daily
Study: 20234136
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg betamethasone in a single dose (group 2)
Study: 18359663
Drug: PEG-IFN alpha-2b
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN alpha-2b treatment
Study: 12823591
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg/day) for 104 weeks
Study: 12823591
Drug: Lamivudine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (150 mg/day) for 104 weeks with or without 4 months of interferon (IFN) combination
Study: 9010561
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with modified phleum pratense allergenic extracts
Study: 9010561
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with specific IT, only with drugs)
Study: 1379739
Drug: Glycosaminoglycan polysulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosaminoglycan polysulfate (600 LRU daily for 24 weeks)
Study: 6360832
Drug: Calcium-vitamin-D-combination (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin-D-combination (single dose ampoules for peroral application)
Study: 29989855
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (ABVD and BEACOPPescalated)
Study: 19423614
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg daily for 7-10 days
Study: 19423614
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for 7-10 days
Study: 17637587
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam 0.035 mg/kg (Group A)
Study: 17637587
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam 0.035 mg/kg (Group C)
Study: 17637587
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam 0.035 mg/kg (Group D)
Study: 16085789
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 mg-10 mg/day; mean: 5.2 mg/day)
Study: 16085789
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 mg-2 mg/day; mean: 1.0 mg/day)
Study: 12376586
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR 300 mg/d for 26 weeks, increased to 400 mg/d if <5% weight loss at week 12
Study: 7850924
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) administered via intravenous infusion or oral administration
Study: 2262487
Drug: Prophylactic CNS
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic CNS therapy (St. Jude regimen)
Study: 2262487
Drug: Prophylactic CNS
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic CNS therapy (other regimens)
Study: 2262487
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic CNS therapy
Study: 19365010
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of tadalafil
Study: 17039333
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.52 mmol/kg/day in four doses)
Study: 14507122
Drug: Massage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage with music therapy
Study: 14507122
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy only
Study: 8458056
Drug: Aztreonam regimen
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam regimen (2 gm every 8 hours) plus clindamycin (600 to 900 mg q8h) or nafcillin (1.5 gm to 2 gm every 6 hours)
Study: 8458056
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (aminoglycoside) including amikacin (5 mg/kg q8h) plus cefazolin (1 gm q8h) or amikacin (500 mg every 12 hours) plus mezlocillin (4 gm q6h) or tobramycin plus ticarcillin (3 gm to 4 gm q4h)
Study: 2429619
Drug: Regimen PMP
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen PMP (CDDP 60 mg/m2, d 1, MMC 6 mg/m2, d 3, d 10 and PEP 5 mg/m2, d 3-7)
Study: 2429619
Drug: Regimen PM
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen PM (CDDP 60 mg/m2, d 1 and MMC 6 mg/m2, d 3, d 10)
Study: 2429619
Drug: Regimen PMF
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen PMF (CDDP 60 mg/m2, d 1, MMC 6 mg/m2, d 3, d 10 and FT 800 mg/body, d 3-21)
Study: 26642949
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: two intra‐articular sacroiliac injections of local anaesthetic/corticosteroid guided by ultrasound in 7 days